Navigation Links
Suits Commenced Against Maker of Prescription Cleansing Drug
Date:12/23/2009

GREENSBORO, N.C., Dec. 23 /PRNewswire/ -- Suits were commenced Dec. 23, 2009 in North Carolina for four users who allege kidney damage due to the use of OsmoPrep, a prescription drug used to cleanse the intestines in preparation for a colonoscopy. (Holshouser et al v. Salix Pharmaceuticals, Ltd. and Salix Pharmaceuticals. Inc.)

The actions are against two Morrisville, N.C., pharmaceutical companies, Salix Pharmaceuticals, Ltd., and Salix Pharmaceuticals, Inc. ( SLXP). The company, which specializes in marketing gastrointestinal drugs, began selling OsmoPrep in 2006. It had over $30 million in sales in 2008.

OsmoPrep contains two types of sodium phosphates, which work by drawing water in the bowels. A large number of pills are taken the day before and the day of the colonoscopy. Salix also sells a product, Visicol, with similar chemicals and has the same purpose.

In December 2008, after receiving a number of reports of kidney injury, the FDA required Salix to place a black box warning on the product, as to serious kidney damage occurring after use of OsmoPrep and also Visicol. A black box warning is the most strict type of warning that the FDA can force a drug supplier to use in its labeling.

Also as a condition for continuing to market OsmoPrep, the FDA required Salix to perform what is known as a REMS evaluation--Risk Evaluation and Mitigation Strategies. These are designed to determine which population is more at risk in using the product, such as older person, those who are dehydrated or have pre-existing kidney damage, and those concurrently on other drugs.

The liquid form of these oral phosphates had been used in Fleet Phospho-Soda, an over-the-counter product manufactured by C. B. Fleet in Virginia. Fleet withdrew this product from the market in December 2008 in response to a similar request from the FDA to enhance its warnings.

The four plaintiffs in this suit
'/>"/>

SOURCE Rheingold, Valet, Rheingold, Shkolnik & McCartney LLP
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent
2. Arnold & Itkin Announces Lawsuits Over Defective Pain Pumps
3. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
4. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
5. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
6. Molnlycke Drives Home the Fight Against Staph and Other MRSA Infections
7. Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug Droperidol Unnecessary
8. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
11. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
(Date:1/22/2015)... 22, 2015  ViewRay™, a privately held medical device company, ... distributor agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: ... the treatment of cancer in Japan ... world,s first and only MRI-guided radiation therapy system that ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... sodium injection) were also ... within 90 days-, BRIDGEWATER, N.J., Dec 10 ... total hospital,direct medical costs associated with VTE treatment are ... the use of low-molecular weight heparin,(LMWH) vs. unfractionated heparin ...
... 10 Alfacell Corporation,(Nasdaq: ACEL ) today reported ... The company recorded a net loss of approximately ... for the fiscal quarter ended Oct. 31,compared to a ... and diluted,common share, for the first quarter of fiscal ...
Cached Medicine Technology:Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 2Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 3Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 4Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 5Alfacell Reports Financial Results for First Quarter of Fiscal 2008 2Alfacell Reports Financial Results for First Quarter of Fiscal 2008 3Alfacell Reports Financial Results for First Quarter of Fiscal 2008 4Alfacell Reports Financial Results for First Quarter of Fiscal 2008 5
(Date:1/22/2015)... As interest in the value of spiritual ... worldwide, Rev. Eric J. Hall , president and CEO ... will be the keynote speaker on January 27 at an ... system. , The conference, “Hope and Resilience: Innovative and Interdisciplinary ...
(Date:1/22/2015)... released a new blog post presenting a list of vehicles that ... , Some types of vehicles cannot be covered under an ordinary ... to see if their vehicle qualifies for auto insurance coverage. ... cars that cannot be covered by a plan. Clients have little ...
(Date:1/22/2015)... VA (PRWEB) January 22, 2015 Step ... power at the Science Museum of Virginia. Wicked Plants, ... , Wicked Plants unearths 75 poisonous, carnivorous and diabolical ... through each room to uncover the biochemical, physical and ...
(Date:12/26/2014)... 2014 The US represents the largest market ... 2013, GlobalData’s forecast estimates that sales of branded therapies were ... to the high incidence of the disease, high drug treatment ... and China. Increased sales of CRC therapies over the forecast ...
(Date:12/26/2014)... Cooking and warming equipment has ... score reflects slightly positive negotiation conditions for buyers, stemming from ... a low level of price volatility. “However, buyer power is ... warming equipment and high volatility in the world price of ...
Breaking Medicine News(10 mins):Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3
... brain area less, MRI scans show , SATURDAY, Jan. 23 ... of themselves have less activity in the frontal lobes of ... more you activate a portion of your frontal lobes, the ... you view yourself as desirable or better than your peers, ...
... fampridine-SR for the treatment of multiple sclerosis. Researchers at ... the effects of the drug in MS for more than ... some neurological functions in people with the disease and ... the FDA. "This is a good day ...
... Researchers at the medical university Karolinska Institutet have created ... be activated by blue light. Shining blue light on ... walking-like motor activity. The findings, which are published in ... potential significance to the recovery of walking after spinal ...
... of Congo erupted, spewing lava from its southern flank and ... of Sake could be under threat. Fears were also ... imminent at the nearby Nyiragongo volcano, which devastated the city ... been using a long series of space images from ESA,s ...
... at The Royal Melbourne Hospital and the University of ... a common type of childhood leukaemia T cell ... lead to improved treatments for this disease and help ... McCormack and Dr David Curtis of the Rotary Bone ...
... proteomic analyses of blood samples may help physicians identify ... women, according to an article published in the February ... Proteomics is the study of proteins, particularly their structure ... leading cause of cancer-related death. More than 21,500 women ...
Cached Medicine News:Health News:Self-Image Linked to Activity in Frontal Lobe of Brain 2Health News:Researchers welcome new multiple sclerosis drug 2Health News:Researchers welcome new multiple sclerosis drug 3Health News:Scientists shed new light on walking 2Health News:Congo receives help from space after volcano eruption 2Health News:Congo receives help from space after volcano eruption 3Health News:Congo receives help from space after volcano eruption 4Health News:Scientists discover cells critical to childhood leukemia 2Health News:Ultrasound plus proteomic blood analyses may help physicians diagnose early-stage ovarian cancer 2
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
CRP Liquid Conrtols level 3...
The GLU method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of glucose in serum, plasma, urine and cerebrospinal fluid....
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
Medicine Products: